echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > PD-L1 Single Anti-Bavencio plus Asitini: Recommended by NICE in the UK as a first-line treatment for advanced kidney cancer.

    PD-L1 Single Anti-Bavencio plus Asitini: Recommended by NICE in the UK as a first-line treatment for advanced kidney cancer.

    • Last Update: 2020-08-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The National Institute for Health and Care Excellence (NICE) recommends that Merck and Pfizer's immunotherapy bavenio (avelumib) be combined with Inlyta (axinitib) for first-line treatment syntil-end renal cell carcinoma (RCC). The prognosis of patients with late
    RCC is poor, with a five-year survival rate of only 12%, so more first-line treatment options are urgently needed.
    picture source: Bavencio is an immune checkpoint inhibitor for PD-L1, while aschitinib is a strong and highly selective tyrosine kinase inhibitor that acts on vascular endothelial growth factor receptors (VEGFR) 1, 2 and 3.
    the two drugs play complementary anti-tumor effects on two key pathways of tumor growth. in the JAVELIN Renal 101 study,
    , the combination of drugs reduced the risk of disease progression or death by 31% and the median progression-free survival by 5.3 months, regardless of PD-L1 status.
    research is under way to determine the overall survival benefits. Professor Amit Bahl, an expert in kidney cancer at
    , said: "This positive recommendation from NICE provides an effective and well-tolerated treatment option for patients with advanced kidney cancer.
    combination can improve outcomes in patients with advanced kidney cancer, immunotherapy and tyrosine kinase inhibitors provide new treatment options for patients.
    "
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.